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Summary CA 242, a novel tumour carbohydrate antigen present in serum (upper limit of normal values:
20.0 U ml-'), has been measured in a group of 102 pathologically confirmed non-small cell lung cancer
patients. The aim of the present prospective study was to identify any relationship between pre-treatment
serum CA 242 level and different features of lung cancer including prognosis. Serum CA 242 was measured
using the delayed europium lanthanide fluoroimmunometric assay. Sensitivity and specificity were 28.5% and
95.6% respectively. Its level was significantly lower in squamous cell carcinoma in comparison with non-
squamous histologies (adenocarcinoma and large cell carcinoma). The CA 242 level was higher in metastatic
disease (median: 15.3 U ml-') in comparison with non-metastatic (median: 7.9 U ml-'; Mann Whitney U test;
P<0.003), and increased significantly from stage I to stage IV. In 50 patients who underwent chemotherapy,
the serum CA 242 level was higher in non-responder patients when compared with responders (median:
16.8 U ml -' and 9.5 U ml-' respectively; Mann Whitney; P<0.02). Univariate analysis of the entire popula-
tion showed serum CA 242 levels were not related to survival. However, patients with unresectable non-small
cell lung cancer and elevated CA 242 level proved to have a significantly shorter survival than those with a
CA 242 <20 U ml-'. In Cox's model analysis, stage of the disease and performance status were the only
significant determinants of survival. We conclude that a high level of serum CA 242 (1) is significantly related
to the stage of disease, (2) predictive of no response to chemotherapy but seems to add weak prognostic
information to stage of disease and performance status, the main prognostic determinants of non-small cell
lung cancer.
Lung cancer is the leading cause of cancer mortality for men
and its incidence is increasing in women (Stjernsward et al.,
1988). The WHO pathologic description of malignant tu-
mours classifies lung cancers into four groups (World Health
Organization, 1982): Small cell lung cancer (SCLC), squa-
mous cell carcinoma, primary adenocarcinoma and large cell
carcinoma. Small cell lung cancer has neuroendocrine proper-
ties which confer on this tumour specific biological and
clinical features. From a prognostic and therapeutic point of
view, squamous cell carcinomas, adenocarcinomas and large
cell carcinomas are pooled in a non-small cell lung cancer
(NSCLC) group (Mulshine et al., 1986).
Serum carcinoembryonic antigen (CEA) and tissue poly-
peptide antigen (TPA) have been extensively studied with
regard to sensitivity, specificity and applicability in the man-
agement of lung cancer (Muller et al., 1985; Salvati et al.,
1985; Buccheri et al., 1986; Buccheri et al., 1987). Both
sensitivity and specificity of TPA are higher than those of
serum CEA, and patients with an elevated serum TPA level
have a worse prognosis on univariate analysis. Serum neuron
specific enolase (NSE), a neuroendocrine marker of con-
siderable interest in the management of SCLC (Jorgensen et
al., 1989), has been proposed as a marker ofchemosensitivity
for NSCLC (Carney et al., 1988); however, only 15% of
NSCLC patients present an elevated serum NSE level at time
of diagnosis (Ariyoshi et al., 1986). Thus, new tumour
markers are needed to help the management of NSCLC.
Carbohydrate antigens might be putative markers inasmuch
as they are expressed following neoplastic transformation of
the respiratory epithelium (Tockman et al., 1992).
CA 242 is a novel mucin related marker which detects an
epitope on a protein captured by an anti-CA 50 monoclonal
antibody (Nilsson et al., 1988; Haglund et al., 1989; Nilsson
et al., 1992; Pasanen et al., 1992). In a previous trial, CA 50
has been shown to be raised in 55% of NSCLC (Cooper,
1991). The aim of the present prospective study was to
identify any relationship between pre-treatment serum CA
242 level and different features of lung cancer including
chemosensitivity and prognosis.
Patients and methods
Patients
One hundred and two consecutive NSCLC patients referred
to the Montpellier University Hospital between February
1990 and July 1991 were prospectively entered in the study
(Table I). All patients had pathologically confirmed NSCLC.
Table I Patient characteristics
No
M/F
Mean age (s.d., range)
Histology
SQC
ADE
LCC
Performance status
0
1
2
3
Stage of disease
I & II
Illa
IIIb
IV
Weight loss (%)
0
0-5
>5
102
86/16
61 (11, 32-88)
67
22
13
9
59
26
8
15
21
28
38
63
15
24
Received 3rd September 1992; and in revised form 14 December
1992.
Abbreviations: s.d.: standard deviation; SQC: squamous cell
carcinoma; ADE: adenocarcinoma; LCC: large cell carcinoma.
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Among them were 67 squamous cell carcinomas (SQC), 22
adenocarcinomas (ADE) and 13 large cell carcinomas (LCC)
as defined by the WHO classification (World Health Organ-
ization, 1982). Performance status (PS) was estimated accor-
ding to the Eastern Cooperative Oncology Group (ECOG)
and the percentage of weight loss during the previous 4
months was recorded. Staging was carried out by exhaustive
procedure according to the 4th edition of the UICC TNM
classification (Sobin et al., 1987) and the American Thoracic
Society map of regional pulmonary nodes (Tisi et al., 1982)
(Table I). For all patients staging procedure included clinical
examination, standard chest roentgenography, computed to-
mographic (CT) scan of chest and upper abdomen, fiberoptic
bronchoscopy, liver sonography and bone scanning. Brain
CT scan was done only if clinically required.
Controls
The serum CA 242 level was measured in 275 healthy sub-
jects (220 non-smokers and 55 smokers), data provided by
Dr 0. Nilsson, CANAG AB, Gothenberg.
Treatment decision
Each patient was discussed by a medical panel composed of
thoracic surgeons, chest physicians, radiologists, radiothera-
pists and medical oncologists. Twenty-four patients with
Stage I or II disease or with moderate locally advanced
NSCLC (Illa with resectable nodes metastasis) underwent
surgery in an attempt to achieve complete resection. Fifty
patients with performance status < 2 and distant metastasis
(stage IV) or gross mediastinal involvement (stage IIIB and
stage Illa with more than two ipsilateral mediastinal lymph
node metastases) were eligible for chemotherapy. Best sup-
portive care, including palliative radiation-therapy when
needed, was given to 28 patients with advanced stage and/or
poor performance status. Treatment was decided according
to routine clinical and biological findings and without know-
ledge of the serum CA 242 or CEA levels. Hence, treatment
was not considered as a prognostic variable in this study.
Chemotherapy
Among the 50 patients who entered the chemotherapy trials,
35 received cisplatin containing combinations and 15 vinca-
alkaloid in monochemotherapy. After 11 weeks of treatment,
response to chemotherapy was evaluated using CT scan
measurements of the indicator lesion analysed according to
WHO recommendations (World Health Organisation, 1979).
Twenty-one patients achieved a clinical response (three com-
plete responses and 18 partial responses). Twenty-two pa-
tients did not respond to chemotherapy (14 patients with
progressive diseases and eight with stable diseases). Three
patients were not evaluable for response owing to an early
death four others have not, until now, been evaluated.
Biochemical measurements
A blood sample was taken from each patient at presentation,
the serum separated and stored at - 800C until tested.
Serum CA 242 and CEA were both measured using the
delayed europium lanthanide fluoroimmunometric assay
(DELFIA, Pharmacia Diagnostics AB, Uppsala, Sweden).
Total lactate dehydrogenase (LDH) assays were done follow-
ing the Deusch Chemical Society recommendations by meas-
uring its activity using pyruvate as a substrate (Bio-Merieux,
France).
The upper limits of normal values were as follows: CEA:
5.0 ngml'; CA 242: 20.0 Uml' (Nilsson et al., 1988; Hag-
lund et al., 1989; Nilsson et al., 1992); LDH: 330 U l-;
Alkaline phosphatase: 220 U/1-'; leukocytes: 8,000 il-1. The
lower limits of normal values were 32 g 1I for albumin and
135 mmol 1' for serum sodium.
All sera samples were assayed blind ofclinical information.
Statistics
Receiver Operating Characteristic (ROC) curve was construc-
ted in order to analyse the relationship between sensitivity
and specificity and area under the ROC curve was calculated
(Beck & Shultz, 1986). Results of the distribution of serum
CA 242 in different subset of patients were expressed as
median and variation was expressed as interquartile range.
Non parametric statistical analyses were used as the serum
tumour markers were not normally distributed. Differences
between two independent groups were determined by means
of Mann Whitney U test; differences between more than two
groups were determined by means ofKruskal Wallis one-way
analysis of variance; a P level <0.05 was considered as
significant. Correlation coefficients were calculated to com-
pare the CA 242 level with CEA levels. Proportion of ele-
vated serum CA 242 level in sub-groups was compared by X2
test with Yates' correction where appropriate. Survival was
defined as the time from the date of sampling to the date of
death. No patient has been lost from sign during follow-up.
Probability of survival was estimated by the Kaplan-Meier
method (Kaplan & Meier, 1958). Single variable survival
analyses were done by means of Wilcoxon and log-rank tests
and multivariate regression was done with the Cox's model
(Cox, 1972). There were 13 variables in the model: Serum
CA 242 was examined as normal (< 20 U ml-') or elevated
(>20 U ml-') as were the other biological variables (CEA,
LDH, alkaline phosphatase, and leukocytes) according to
their respective upper normal limits and age as less or equal
to and over 50 years-old. Other variables were sex, histology,
stage, weight loss, performance status, serum sodium and
albumin. Survival was analysed using the SAS software
package.
Results
Tumour marker distribution at presentation
The median and interquartile range [IR] of serum CA 242
and CEA levels are presented in Table II. In healthy subjects
serum CA 242 level (median: 6.0; [IR]: 3.0-10.0) was
significantly lower when compared with that of NSCLC pat-
ients (Mann Whitney U test; P<0.001) and did not differ
according to smoking habits. Area under the ROC curve was
0.67±0.03 (Figure 1). Using 20Uml-1 as the upper limit,
sensitivity, specificity and accuracy were 28.5%, 95.6% and
77.4% respectively. Positive and negative predictive values
were 70.7% and 78.3% respectively.
Serum CA 242 andhistology
The median [IR] serum CA 242 for SQC, ADE and LCC
were 10.0 [4.7-17.4], 17.1 [5.9-60.0] and 9.5 [5.6-19.0] U
ml- ', respectively. The serum CA 242 level differed when the
histological type of NSCLC was considered but this
difference showed only a trend (Kruskal-Wallis test;
P<0.07, Table III). However, when LCC and ADE were
pooled in a non-squamous cell carcinoma group, serum
Table II Tumour marker distribution at presentation
Frequency
Median Range Interquartile Cut-off ofelevatedlevel
CA 242 (U ml-') 11.0 < 1-5396 5.0-27.3 20 29/102 (28.5%)
CEA(ngml-') 4.5 0.6-5000 3.0-18.0 5 58/102(59%)
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Figure 1 Receiver Operating Characteristic curve for serum
CA 242 (AUC
= 0.67 ± 0.03).
CA 242 level (median: 12.9; [IR] 5.8-50.0) was significantly
higher when compared with the SQC group (10.0 [4.7-17.4];
Mann Whitney; P<0.03).
Serum CA 242 distribution and extent of disease
Among the 102 patients, 64 showed no clinical evidence of
metastasis after staging and 38 showed metastasis. The serum
CA 242 level was significantly higher in metastatic (extensive)
disease (median [IR]: 15.3 [7.2 50.2] U ml-') in comparison
with non-metastatic (limited) disease (median [IR] 7.9 [4.7-
16.3]U ml-'; Mann Whitney U test; P<0.003). Moreover,
the distribution of serum CA 242 levels according to stage
showed a significant elevation from stage I to stage IV
[median [IR]: stage I & II, 5.9 [4.1-17.0]; stage tIIa, 8.0
[4.8-13.0]; stage TIIb, 10.5 [4.8-22.2]; stage IV, 15.3 [7.2-
50.2] U ml'- ; Kruskal-Wallis; P <0.03, Table III). The dis-
tribution of serum CA 242 level did not differ according to
nodal status.
Serum CA 242 distribution and performance status
The distribution of serum CA 242 level did not differ
significantly according to PS (Kruskal-Wallis KW = 1.29;
P = 0.26). These results might be explained by the small
number of patients in some groups. It has been reported that
patients with a good PS (<2) had a better outcome than
patients with a PS > 2 at presentation (Kanda et al., 1988).
Thus, we compared the serum CA 242 distribution in these
two groups of patients. There was no difference between the
serum CA 242 level in PS <2 patients and the one with PS
) 2 patients (median [IR] respectively 11.0 [5.1-27.1] and
10.2 [4.9-34.9] U ml1' Mann Whitney; P = 0.45, Table III).
The serum CA 242 level did not differ significantly accor-
ding to weight loss at presentation (Kruskal Wallis; P=
0.13).
As the incidence of a serum CA 242 level over 20 U ml1
was higher in stage IIIb-IV NSCLC we analysed whether or
not the marker differed according to performance status and
weight loss within this patient subgroup. Although the serum
CA 242 tended to be higher in patients with poor perfor-
mance status or weight loss the differences did not reach
statistical significance (Mann Whitney U test).
Serum CA 242 distribution and operability
The serum CA 242 level in patients who underwent a resec-
tion was significantly lower (median: 5.9 U ml-'; [IR] 4.4-
13.7) in comparison with patients with inoperable disease
(median: 12.2 U ml'; [IR] 5.6-35.0; Mann Whitney P=
0.02).
Serum CA 242 and tumour response to chemotherapy
Among the 21 patients who achieved a response, three had a
pre-treatment serum CA 242 level > 20 U ml-'. In contrast
9/22 non-responder patients had an elevated pre-treatment
serum CA 242 level (X2 test P<0.05). In responder, stable
disease and progressive disease groups the median and [IR]
values of serum CA 242 were 9.8 U ml-' [4.3-16.4], 13.4 U
ml-' [7.9-26.9] and 16.8 U ml-' [11.0-35.0] respectively.
These values did not significantly differ (Kruskal Wallis,
P< 0.1). However, the serum CA 242 level in patients with a
progressive disease (median: 16.8 U ml-'; [IR] 11.0-35.0)
was significantly higher when compared with the serum
CA 242 level in responder patients (9.5; [IR] 4.7-15.7) U
ml-'; Mann Whitney; P<0.02; Figure 2).
Relationship ofserum CA 242 and serum CEA levels
The comparison of serum CA 242 level vs serum CEA dem-
onstrated a significant correlation (r = 0.52; P<0.01).
Survival
Univariate analysis showed that patients with a high serum
CA 242 pre-treatment level did not prove to have a
Table III Distribution of serum CA 242 according to different patient
characteristics
CA 242 (Uml-')
420 >20-<,40 >40-,<60 >60-<80 >80
Patient subgroups n (%) n (%) n (%) n (%) n (%)
Histology
ADE 12 (54) 2 (9) 3 (14) 0 (0) 5 (23)
SQC 51 (76) 6 (9) 5 (8) 2 (3) 3 (4)
LCC 10 (77.5) 1 (7.5) 0 (0) 1 (7.5) 1 (7.5)
Stage
I & II 12 (80.5) 1 (6.5) 1 (6.5) 1 (6.5) 0 (0)
Illa 18 (86) 2 (9) 1 (5) 0 (0) 0 (0)
IlIb 21 (75) 4 (14) 2 (7) 0 (0) 1 (4)
IV 22 (58) 3 (8) 4 (11) 1 (3) 8 (20)
Performance status
0-1 49 (72) 8 (12) 5 (7) 1 (1.5) 5 (7.5)
2-3 24 (70) 3 (9) 2 (6) 1 (3) 4 (12)
all 73 (71) 11 (9) 7 (8) 2 (3) 9 (9)
Abbreviations: SQC: Squamous cell carcinoma; ADE: adenocarcinoma; LCC: large
cell carcinoma.1426 J.-L. PUJOL et al.
>260 1
140 i
120 H
E
D
c,.
c1.J
0q
100 H
80 V
60 K
40 V
20
0 .s
Response
,. ;,,,, ,,,,,,4@,,,,,
-~~~~~~~~~~~~~~a0
Figure 2 Serum CA 242 distribution according to response to chemotherapy. Horizontal
quartile range.
significantly shorter overall survival than those with a normal
level (Wilcoxon, P = 0.08; log rank, P = 0.14; Figure 3).
However, patients with unresectable NSCLC and elevated
CA 242 had a significantly shorter survival than those with a
CA 242 under cut-off value (median survival 163 and 242
days respectively; log rank test; P = 0.03; Figure 4). Separate
survival analyses showed a significant effect of the stage of
the disease, a 2 or 3 performance status, presence of weight
loss, low serum albumin and elevated serum LDH (Table
IV). No difference in overall survival was seen when his-
tological type, age, sex, serum sodium, alkaline phosphatase
and serum CEA level were considered.
With Cox's model analysis, stage-grouping of the disease
(coeffiicient = 0.71; P = 0.0019) and performance status (co-
efficient = 0.54; P = 0.005) were the only significant deter-
minants of survival. Other variables including pre-treatment
serum CA 242 and CEA level were removed from Cox's
model.
Discussion
The results of this study suggest that serum CA 242 level has
a greater sensitivity in non-squamous histologies than in SQC
and that its distribution in NSCLC is significantly related to
stage of the disease. Interestingly, the distribution of serum
CA 242 differs according to clinical response to chemo-
therapy inasmuch as responder patients had a significantly
lower serum level of this marker when compared with
patients in whom the disease was not controlled. However,
the level of CA 242 seems to be only a weak prognostic
factor as stage of disease and performance status remain the
only two prognostic determinants in multivariate analysis.
Surgery is the main treatment of low stage NSCLC
(Naruke et al., 1988). For the remaining patients, NSCLC is
considered as a systemic disease, sometimes at the micro-
scopic stage, rather than clinically evident (Gregor, 1991).
Theoretically, such a systemic disease requires a systemic
treatment whether given alone or in a combined modality
treatment including radiation therapy to improve local cont-
rol. However, sensitivity of NSCLC to cytotoxic agents is
low and survival benefit for unresectable patients obtained by
chemotherapy, although well demonstrated, remains poor
bar = median value; columns = inter-
(Rapp et al., 1988). Thus, the treatment of locally advanced
or metastatic NSCLC is still a subject of controversy
(Gregor, 1991). So far, there is no standardised
chemotherapy regimen and many concepts are still being
tested by controlled studies. One of the most impressive
features of NSCLC in such trials is the high heterogeneity of
response and prognosis among a group of patients with
NSCLC. Therefore, tumour markers able to predict tumour
response and prognosis might be a useful tool in the manage-
ment of this disease.
Several markers have been proposed in this setting. CEA is
the most widely studied. The sensitivity and specificity of
CEA in lung cancer are 33 and 89% respectively (Buccheri et
al., 1987). In an early study involving 131 patients with lung
cancer a high level of serum CEA was predictive of poor
prognosis in the unresectable group (Dent et al., 1978). In a
more recent study of 98 patients the value of CEA as a
prognostic marker was confirmed (Buccheri et al., 1986) but
another study published by the same group 1 year later with
a larger number ofpatients failed to confirm this (Buccheri et
al., 1987). It may be underlined, that, in all these studies, the
value of CEA as a prognostic marker was analysed in
populations of patients having lung cancer of any histology
(i.e. pooling SCLC and NSCLC). This perturbs the inter-
pretation of the results because it is now demonstrated that
CEA level has a prognostic influence on patients with SCLC
(Gronowitz et al., 1990). Moreover, only univariate analyses
of survival have been done and, inasmuch as CEA is related
to disease extent, its value as an independent prognostic
variable is questionable. This is emphasised by the results of
another study of 10 serum proteins measured in 215 lung
cancer patients (Muller et al., 1985). CEA was not statis-
tically related to survival whichever operable or inoperable
patients were considered, as is also the case in our study.
In our study we tested a novel tumour associated antigen,
CA242 in NSCLC. This mucin-related marker detects an
epitope on a protein captured by an anti-CA 50 monoclonal
antibody (Nilsson et al., 1988; Haglund et al., 1989). This
tumour marker has been studied extensively in pancreatic
carcinoma (Pasanen et al., 1992) and in other gastro-intes-
tinal cancers (Nilsson et al., 1992). Sensitivity and specificity
of CA 242 were higher than CA 50 in colo-rectal cancer. Our
results showed a lower accuracy of CA 242 in NSCLC. The
No change Progression
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Figure 3 Probability of survival of all patients with normal and abnormal pre-treatment serum CA 242 level.
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Figure 4 Probability of survival of patients with unresectable non-small cell lung cancer according to pre-treatment CA 242 level.
low sensitivity of the detection of this tumour marker in the
serum ofNSCLC patients clearly shows that it is of no use in
a diagnostic setting. There was a relationship between stage
of disease and serum CA 242 level; however, it is not possible
to determine resectability using serum CA 242 level as some
patients with metastatic disease had normal levels. Moreover,
in this study we observed that serum CA 242 values of stage
IIIa (marginally operable) and stage IIIb (usually inoperable)
are close together. Although we found a relationship between
serum CA 242 level and operability, it may be suggested that
serum CA 242 will add little information for deciding whe-
ther or not a complete resection can be achieved in locally
advanced NSCLC.
CA 242 seems to be a more promising tumour marker in
the unresectable group. We studied a non-small cell lung
cancer population with a high proportion of locally advanced
or metastatic diseases, It has been extensively published that
these patients proved to have a short survival (Mulshine et
al., 1986; Gregor, 1991; Rapp et al., 1988); therefore, chemo-
therapy or chemotherapy/radiotherapy combination may be
proposed (Gregor, 1991; Rapp et al., 1988). In our patients
who underwent chemotherapy, a high pre-treatment level was
2.0
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Table IV Significant prognostic factors in the entire population
P value
Factor and level Median survival (days) Wilcoxon Log rank
Stage
I & II 235 0.0001 0.0001
lIla 326
Illb 208
IV 137
Performance status
0-1 302 0.0001 0.0001
2-3 136
Weight loss
No weight loss 282 0.024 0.019
0-5% 152
>5% 204
Albumin (g/l)
> 32 279 0.008 0.038
<32 187
Lactate dehydrogenase (U1')
< 330 283 0.022 0.049
>330 167
predictive of a rapid progression of the disease; moreover,
serum CA 242 levels are related to survival in the inoperable
patient group. As few markers are available at present for
advanced NSCLC, CA 242 might be of interest in the medi-
cal management of this disease. However, we must emphasise
that in Cox's regression model, stage of the disease and
performance status remained the only significant determinant
of prognosis suggesting that the information brought by
CA 242 and LDH add little to the management of NSCLC.
The authors wish to thank Mrs Jo Baissus for help in preparing the
manuscript. This work was supported by grant from the French
League Against Cancer.
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